HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

hemantane

an antiparkinsonian drug

Networked: 7 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Alicyclic Hydrocarbons: 1
      - Cycloparaffins: 6
        Adamantane: 182
        hemantane: 7
    - Bridged-Ring Compounds: 1
      - Adamantane: 182
        hemantane: 7

Experts

1.	Nepoklonov, A V: 4 articles (01/2016 - 01/2011)
2.	Val'dman, E A: 4 articles (01/2014 - 01/2004)
3.	Voronina, T A: 4 articles (01/2014 - 01/2004)
4.	Ivanova, E A: 3 articles (01/2014 - 01/2011)
5.	Kapitsa, I G: 3 articles (01/2014 - 01/2011)
6.	Kolik, L G: 2 articles (04/2019 - 12/2017)
7.	Kokshenev, I I: 2 articles (01/2014 - 01/2011)
8.	Konstantinopolsky, M A: 1 article (04/2019)
9.	Nadorova, A V: 1 article (12/2017)
10.	Seredenin, S B: 1 article (12/2017)

Related Diseases

1.	Parkinson Disease (Parkinson's Disease) 01/01/2012 - "[Study of hemantane effects in rats on a model of early (premotor) stage of Parkinson's disease]." 01/01/2012 - "Results obtained, together with data on hemantane mechanism of action, allow hemantane to be considered as a promising drug for the treatment of Parkinson's disease with potential to decrease the rate of disease progression when administered on early stages." 01/01/2016 - "Potential neuroprotective activity of the novel antiparkinsonian drug hemantane (hydrochloride N-2-(adamantyl)-hexamethylenimine) in comparison to amantadine has been studied in various regimes of administration on human neuroblastoma SH-SY5Y cell line injury induced by 6-hydroxydopamine (6-OHDA), which is used as in vitro model of dopaminergic neurons for Parkinson's disease. "
2.	Parkinsonian Disorders (Parkinsonism) 01/01/2004 - "Acute of subchronic (7-day) pretreatment with hemantane prevented the development of EEG changes typical of parkinsonism. " 01/01/2011 - "[Comparative study of amantadine and hemantane effects on development of levodopa-induced dyskinesia in rat model of parkinsonian syndrome]." 01/01/2014 - "[Influence of hemantane in injectable dosage form on levodopa-induced dyskinesia in rats with model parkinsonian syndrome]."
3.	Dyskinesias (Dyskinesia) 01/01/2011 - "Chronic administration of levodopa and benserazide together with hemantane (10 mg/kg) slows down the development and decreases the magnitude of levodopa-induced abnormal involuntary movements as measured for limb, orolingual and rotatory movements." 01/01/2011 - "[Comparative study of amantadine and hemantane effects on development of levodopa-induced dyskinesia in rat model of parkinsonian syndrome]." 01/01/2014 - "[Influence of hemantane in injectable dosage form on levodopa-induced dyskinesia in rats with model parkinsonian syndrome]."
4.	Disease Progression 01/01/2012 - "Results obtained, together with data on hemantane mechanism of action, allow hemantane to be considered as a promising drug for the treatment of Parkinson's disease with potential to decrease the rate of disease progression when administered on early stages."
5.	Neuroblastoma 01/01/2016 - "Potential neuroprotective activity of the novel antiparkinsonian drug hemantane (hydrochloride N-2-(adamantyl)-hexamethylenimine) in comparison to amantadine has been studied in various regimes of administration on human neuroblastoma SH-SY5Y cell line injury induced by 6-hydroxydopamine (6-OHDA), which is used as in vitro model of dopaminergic neurons for Parkinson's disease. " 01/01/2016 - "[COMPARISON OF CYTOPROTECTIVE EFFECTS OF HEMANTANE AND AMANTADINE UNDER CONDITIONS OF 6-HYDROXYDOPAMINE NEUROTOXIN ACTION ON CULTURED HUMAN NEUROBLASTOMA CELLS]."

Related Drugs and Biologics

1.	Levodopa (L Dopa)
2.	Amantadine (Aman)
3.	Oxidopamine (6 Hydroxydopamine)
4.	N-Methyl-D-Aspartate Receptors (NMDA Receptors)
5.	Neurotoxins
6.	Morphine (MS Contin)
7.	Dosage Forms (Dosage Form)
8.	Benserazide
9.	Adamantane

Related Therapies and Procedures

1.	Injections